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The post-vaccine microevolution of 
invasive Streptococcus pneumoniae
Amelieke J. H. Cremers1,*, Fredrick M. Mobegi1,2,*, Marien I. de Jonge1, Sacha A. F. T. van 
Hijum2, Jacques F. Meis3,4, Peter W. M. Hermans1,†, Gerben Ferwerda1, Stephen D. Bentley5 
& Aldert L. Zomer1,2
The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic population of 
Streptococcus pneumoniae in pediatric carriage. Little is known however about pneumococcal 
population genomics in adult invasive pneumococcal disease (IPD) under vaccine pressure. We 
sequenced and serotyped 349 strains of S. pneumoniae isolated from IPD patients in Nijmegen 
between 2001 and 2011. Introduction of PCV7 in the Dutch National Immunization Program in 2006 
preluded substantial alterations in the IPD population structure caused by serotype replacement. No 
evidence could be found for vaccine induced capsular switches. We observed that after a temporary 
bottleneck in gene diversity after the introduction of PCV7, the accessory gene pool re-expanded 
mainly by genes already circulating pre-PCV7. In the post-vaccine genomic population a number of 
genes changed frequency, certain genes became overrepresented in vaccine serotypes, while others 
shifted towards non-vaccine serotypes. Whether these dynamics in the invasive pneumococcal 
population have truly contributed to invasiveness and manifestations of disease remains to be 
further elucidated. We suggest the use of whole genome sequencing for surveillance of pneumococcal 
population dynamics that could give a prospect on the course of disease, facilitating effective 
prevention and management of IPD.
The bacterial pathogen Streptococcus pneumoniae remains an important cause of pneumonia and menin-
gitis worldwide, causing an estimated 1.6 million deaths annually1. Immunization with a 7-valent pneu-
mococcal conjugated vaccine (PCV), both in young children2 and the elderly3, has been demonstrated 
to be highly efficacious in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. 
Moreover, after the introduction of routine pediatric vaccination, an additional decrease in vaccine-type 
pneumococcal infections occurred, both in pediatric carriage4,5 as well as in IPD at all ages6, indicative 
of a herd immunity effect. However, in all regions where routine PCV vaccination has been introduced, 
we see replacement in pneumococcal carriage and disease by non-vaccine serotypes7–9, which at least 
partially abrogates the preventive effect of vaccination. In the Netherlands, the number of reported cases 
of IPD has not decreased after vaccination due to full replacement by non-vaccine serotypes10.
Currently available pneumococcal vaccines target the pneumococcal polysaccharide capsule. Although 
over 90 antigenically distinct pneumococcal capsules (denominated as serotypes) are known to date, only 
a selection of 7 serotypes (later extended to 10 and 13) is included in the PCV, based on modelling 
vaccination effects by the frequency and the propensity for invasiveness for each serotype11,12. Whereas 
the polysaccharide capsule is essential for the pneumococcus to cause IPD13, recent publications suggest 
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that true determinants of invasiveness may lay underneath the pneumococcal capsule, represented by 
variations on the pneumococcal genome14–18, which should be included in modelling vaccine effects19.
Since the introduction of routine pediatric immunization with PCV, several studies have detailed 
pneumococcal genomic epidemiology in pediatric carriage and otitis media under vaccine pressure. They 
all demonstrated that the pneumococcal genomic structure of pediatric carriage remained fairly stable, 
and that serotype replacement occurred mainly through expansion of previously existent clones20–25. The 
single study that examined whole pneumococcal genomes, including virulence factors, reported little 
effect on the accessory genome at the overall pneumococcal carriage population level despite massive 
serotype replacement26. However, the effect of pneumococcal vaccination on whole genome epidemiol-
ogy of invasive pneumococcal disease remains unexplored, although it may hold invaluable information 
on understanding the long term effects of mass vaccination, especially with regard to changes in clin-
ical manifestation of disease due to the changing prevalence of virulence factors in the pneumococcal 
population.
PCV7 was introduced in the Dutch National Immunization Program in April 2006 while PCV10 was 
introduced in May 2011. In this study, we have sequenced 349 invasive pneumococcal isolates from 2001 
to June 2011, in order to investigate the herd-immunity effect of PCV7 on pneumococcal population 
genomics in IPD.
Results
Cohort and serotype dynamics. We serotyped and sequenced 349 strains of S. pneumoniae isolated 
from an unbiased cohort of IPD patients in Nijmegen, the Netherlands, between 2001 and 2011. In the 
Netherlands, the elderly are not routinely vaccinated against pneumococcal disease, pediatric pneumo-
coccal vaccination coverage has been high (> 94%)27, and penicillin resistance was below 3% during the 
entire study period28. These facts increase the probability that in this cohort, major changes in adult 
IPD epidemiology are due to herd immunity after pediatric immunization. Moreover, risk factors for 
acquiring a pneumococcal infection have not changed for the IPD patients in our study cohort, sug-
gesting that replacement has been a merely pneumococcus-mediated phenomenon. According to our 
analysis, since the 7-valent PCV (PCV7) was introduced in the pediatric Dutch National Immunization 
Program in April 2006, the invasive pneumococcal population structure has altered substantially. Its 
introduction preluded a steady decrease in adult IPD cases caused by the seven serotypes it protects 
against (vaccine types, VTs): 4, 6B, 9V, 14, 18C, 19F, and 23F, supporting a herd immunity effect of PCV7, 
concordant with a previous nationwide study29. In addition, the absolute increase in IPD cases caused 
by non-PCV7 protected serotypes (non-vaccine types, nVTs) observed in the Netherlands30, as well as 
within our cohort31 is suggestive of serotype replacement or capsular switching. Similarly to the pediatric 
pneumococcal carriage study by Croucher et al.26, in our non-vaccinated IPD cohort we observed an 
increase of subtype variants of VTs: 6A, 19A, 23A, and 23B. However, the post PCV7 nVT IPD cases 
were dominated by serotypes 1, 3, 7F, and 8 which may be seen less frequently in carriage cohorts11.
Core genome phylogeny. Phylogeny of the 349 IPD isolates was reconstructed based on a ‘super-
alignment’ of concatenated alignments of genes in 786 out of the 1075 core orthologous groups (OGs)—
containing genes present in a single copy in all isolates. 289 OGs with a dissimilar tree topology and 
branch distance as compared to ribosomal protein encoding genes were excluded as their phylogeny may 
be influenced by recombination or homoplasies. A tight clustering of isolates by serotype was observed 
(Fig 1). Similar to the carriage study by Croucher et al.26, in our IPD study, serotype replacement was 
responsible for the increase in nVTs. The rare cases of capsular switch were probably extant before 
immunization and did not increase upon the introduction of PCV7. It is therefore unlikely that capsular 
switching was induced by vaccine pressure, although larger numbers of isolates may be needed to confirm 
this. Compared to their closest neighbors in the phylogenetic tree, capsular switched strains accumulated 
only between 1 and 10 single nucleotide polymorphisms (SNPs) in their core genome. The majority of 
these SNPs occurred in regions centered on genes involved in resistance to and efflux of antibiotics, syn-
thesis of cell wall proteins, as well as transposases, pili and phage elements (Supplementary Table 1). A 
similar situation with regard to gene insertions or deletions was observed in the capsule switched isolates, 
suggesting phages and transposing elements play a major role in shaping the pneumococcal genome on 
relatively short timescales (Supplementary Table 2). The sequence clusters were based on BAPS analyses, 
and were determined to study if serotype replacement within a serogroup would involve closely related 
core genomes. Although this holds true for serogroup 23, replacement in serogroups 6 and 19 is scattered 
over the phylogenetic tree.
Genome diversity. Analysis of the diversity of the accessory genome among strains revealed a 
significant drop in OG diversity in 2007 shortly after the introduction of PCV7 (p < 0.0001), and a 
re-expansion in subsequent years (Fig. 2); a similar trend is seen for the core OG diversity, although here 
the 95% CIs overlap. This illustrates that vaccination had an early temporary bottleneck effect on IPD 
gene diversity. In concordance with the decreased diversity after vaccination, a considerable number of 
OGs were significantly altered in prevalence, but most of them returned towards equilibrium afterwards 
(Fig. 3). Majority of the OGs that contributed to the re-expansion of diversity in the accessory genome 
after 2007 was comparable to those circulating pre PCV7. The decreased diversity after vaccination when 
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VT stains were steadily removed from the population seems to represent the simultaneous decrease of 
certain sets of VT-related genes. However, the re-expansion of diversity with similar genes, suggests that 
those might now be carried by replacing nVT strains. Such a phenomenon has recently been predicted 
by modeling from pneumococcal carriage genome data32. Aside from this tendency to recover, certain 
OGs dispersed from their prevalence in the original gene pool. Both dynamics will be detailed below. 
Figure 1. Structure of the invasive pneumococcal population. The maximum likelihood phylogeny was 
generated using 59,682 polymorphic sites within a 970,559 bp codon alignment of 755 core OGs with 
similar phylogenetic profiles as ribosomal protein encoding genes in order to exclude genes that were 
acquired by, for example, horizontal gene transfer. The inner bars each represent a pneumococcal strain 
(I) and are colored by capsular serotype. The second circle displays the sequence clusters (II). The year of 
collection is marked by the color (red: pre-PCV7, blue: post-PCV7) and intensity of coloration per year, for 
PCV7 vaccine serotypes (III) and non-vaccine serotypes (IV).
Figure 2. Annual diversity among accessory genomes. The diversity was calculated between strains 
collected within the same year. Using a binary measure of the presence (1) or absence (0) of a gene in each 
accessory OG, diversity among strains was calculated by applying the distance measure described by Dutilh 
et al.47. Core OG diversity was determined by comparing the pairwise distances between isolates from the 
phylogenetic tree per year. Circles: means accessory distance; diamonds: means core OG distance; whiskers: 
95% confidence intervals.
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A second gradual decrease in accessory genome diversity was observed towards 2011. This was not due 
to a distinct decreasing diversity among VT strains post vaccination, as the diversity in the accessory 
genomes remained similar between VT and nVT strains (see Supplementary Figure 1).
Gene dynamics. For the entire cohort, 506 pneumococcal genes were significantly overrepresented 
in the group of VTs, and 223 in nVTs (see Supplementary Table 3). This observation suggests that the 
distribution of particular genes over strains is more clustered in the VT group. Given the low number of 
serotypes in the VT group, it may indicate that also the phylogeny of the accessory genome clusters by 
serotype. Whereas 97 genes were exclusively found in the VTs and 331 genes were unique to the nVTs, 
the average number of unique genes per serotype was equal.
Post PCV7, 105 genes significantly decreased in frequency, among which many phage-related genes 
and transposons that went down along with VTs carrying them. Only 33 genes expanded significantly, 
including mainly ABC-transporters, zinc metallopeptidases and genes facilitating recombination. The 
fact that VT strains had more OGs associated with phages throughout the course of the study may relate 
to the ‘kill the winner’ strategy employed by phages as VT strains had a higher prevalence and would 
therefore be more likely to be a target for phage predation.
Under the selective pressure of herd immunity post PCV7, the rate of adult IPD caused by VTs 
decreased. Those VT strains that still caused IPD after the PCV7 bottleneck more often carried OG0185 
DNA methylase (1.8 fold increase, p = 0.008), OG1539 flippase wzx associated with serogroup 6 (2.3 
fold increase, p = 0.037), and a cluster consisting of 13 Tn5253-related genes (3.7 fold increase, p = 0.02). 
Although the latter are often related to acquisition of antibiotic resistance, all strains concerned were 
fully susceptible to tetracycline and clindamycin, and only 1 was resistant against erythromycin and 
clarithromycin. The patients involved had no notable history indicative of increased antibiotic pressure 
(antibiotics use before admission, comorbidities associated with frequent antibiotics use, nursing home 
residency). Therefore, presence of the Tn5253 cluster may have facilitated maintenance in IPD through 
a different mechanism.
After 2007 the number of adult IPD cases caused by non-vaccine serotypes expanded. Among nVT 
IPD, the proportion of strains carrying OG1150 (toxin antitoxin component HicA) increased post PCV7 
(p = 0.032). Genes that were first observed in nVTs after PCV7 (n = 115) were infrequent. They coded for 
phages, transposons and membrane structures, but also included OG2585 (endonuclease), and OG2354 
(multidrug resistance transporter MdtK). Although the latter is homologous to the MepA multidrug 
transporter of S. aureus, here a different antibiotic resistance pattern was observed. Of the two strains 
carrying MdtK, one isolate was fully susceptible in vitro, while the other was resistant to clarithromy-
cin,33 intermediately susceptible to doxycycline and ofloxacin, but not resistant to fluoroquinolones - the 
substrate of MepA in S. aureus31.
Although capsular switching has been rare, theoretically, individual pneumococcal genes may also 
benefit from translocation to strains with a polysaccharide capsule not targeted by vaccination. We stud-
ied whether individual genes shifted from VT to nVT strains by comparing the odds ratios for linkage 
to VT versus nVT strains before and after the PCV7 bottleneck. Of the 86 genes that displayed increased 
odds for being related to nVTs after PCV7, 72% were previously related to VTs, indicative of a certain 
Figure 3. Temporal stability of accessory gene pool. Odds ratios for prevalence of individual OGs in the 
accessory genome whose frequency significantly altered at bottleneck shortly post PCV7 (2007) or during re-
expansion (2008–2011), compared to pre PCV7 (2001–2006) The X-axis indicates the proportion of isolates 
carrying each OG in 2001 while the Y-axis indicates the log transformed odds ratio of strains carrying each 
OG in 2007 (green dots), and post PCV7 (blue dots), relative to pre PCV7.
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originality to nVT strains. Whether these genes actually benefit from a transition towards nVT strains, 
or contribute to severity of infection remains to be elucidated.
Although after the introduction of PCV7 the overall severity of IPD cases (measured by pneumonia 
severity index) remained stable, higher rates of pleural effusion and empyema have been reported31,34, 
which may be attributed to a changed frequency of virulence factors in the pneumococcal population. 
For instance zinc metalloproteinase C (zmpC), mainly present in nVTs, has been associated with a more 
severe clinical manifestation of IPD and was shown to be expanding17. This illustrates that elimination 
of VTs may result in substitution by nVT strains that potentially confer more severe disease. Modeling 
of vaccination-induced changes in frequency of disease associated genes may therefore be of interest to 
optimize target selection in new generations of pneumococcal vaccines. Such an approach would require 
further exploration of the role of pneumococcal genotypes in the manifestation of human infection.
Conclusions
Despite serotype replacement in pneumococcal disease, after pediatric pneumococcal vaccination with 
PCV7 we observed a temporary bottleneck in gene diversity, which re-expanded mainly by genes already 
present in the original gene pool. Our observations suggest that the introduction of PCV7 has only 
temporarily affected the pneumococcal population, like disease frequency, with the effects lasting up 
to one year. Certain genes in IPD have dispersed from their original prevalence, while others became 
overrepresented in VT, or shifted towards nVT. These changes may influence clinical manifestation of 
disease if these genes are associated with disease. We suggest whole genome sequencing to investigate 
pneumococcal dynamics after vaccination and as such maintain close surveillance of strains in a pop-
ulation; information that could give a prospect on an altered course and severity of disease, facilitating 
effective prevention and management of invasive pneumococcal disease.
Methods
Pneumococcal strain collection, DNA isolation and serotyping. Pneumococcal strains were 
isolated from adults hospitalized with a bacteremic pneumococcal infection at two Dutch hospitals 
between January 2000 and June 2011 as described by Cremers et al.31. The candidates were retrospec-
tively included in the Pneumococcal Bacteraemia Collection Nijmegen (PBCN). This observational 
cohort study was approved by the Local Medical Ethics Committees of both participating hospitals. 
The cohort was divided in pre and post PCV-7 strains as defined by their collection from blood before 
or after January 1 2007. The pneumococcal serotypes were determined using the multiplex PCR analy-
sis35. In case multiplex PCR was inconclusive, serotyping was complemented with the Quellung reaction 
using Pneumococcus Neufeld Antisera (Statens Serum Institute, Copenhagen, Denmark) according to 
the manufacturer’s instructions31. All pneumococcal serotypes were then confirmed using an in-house 
implementation of the Sanger Institute molecular capsular typing (MCT) system36,37.
Genomic DNA preparation and whole genome sequencing. The strains were grown statically 
in 10 ml of Todd Hewitt broth (Merck, Darmstadt, Germany) with 5% yeast extract at 37 °C and 5% 
CO2 to an optical density at 620 nm of 0.2–0.3. The bacterial pellet was washed with 1 ml PBS and DNA 
was extracted using QIAGEN Genomic-tips 20/G and Genomic DNA Buffer Set (both Qiagen, Venlo, 
The Netherlands) according to the manufacturer’s instructions for mini DNA preparations. The con-
centration of extracted genomic DNA was determined using Quant-iT™ PicoGreen® dsDNA Reagent 
(LifeTechnologies, Bleiswijk, The Netherlands) and the TECAN GENios plate reader with Magellan 
software (Tecan, Giessen, The Netherlands) and its intactness was confirmed with gel electrophoresis. 
Genomic DNA was sequenced on an Illumina HiSeq 2000 as paired-end reads of 100 nucleotides.
Genome assembly, mapping and annotation. The strains were assembled using the Sanger 
Institute genomes assembly pipeline. For each strain, Velvet38 was used to create multiple assemblies by 
varying the kmer size between 66% and 90% of the read length. From these assemblies, the one with 
the highest N50 was chosen and contigs that were shorter than the insert size length were removed. The 
resulting assembly was improved by the following steps: The contigs of the assembly were scaffolded by 
iteratively running SSPACE using default settings39. Then, gaps identified as 1 or more N’s, were targeted 
for closure by running 120 iterations of GapFiller40. Genomes were annotated using an in-house imple-
mentation of Prokka41. The genome assemblies were deposited at the European Nucleotide Archive under 
study number ERP001789.
Gene clustering and phylogenetic analysis. All putative coding sequences were translated 
and analyzed by an all-versus-all blastP employing a 10E-15 e-value cut-off and BLOSUM90 matrix. 
TribeMCL42 was used to cluster orthologs by an inflation value of 4 to implement the MCL step, which 
resulted into a total of 3021 OGs. Of these OGs, 1075 were denominated as core OGs as they consisted 
of proteins present in single copies in each of the 349 strains. Protein sequences of these core OGs were 
aligned with MUSCLE43, and subsequently codon translated into nucleotide alignments44. Genes of OGs 
encoding ribosomal proteins from each strain were concatenated into a single ‘ribosomal’ alignment. 
A reference maximum likelihood phylogeny was generated based on this ribosomal alignment using 
RAxML35. Phylogenies for each of the remaining core OGs were also generated separately. Plotting the 
www.nature.com/scientificreports/
6Scientific RepoRts | 5:14952 | DOi: 10.1038/srep14952
Euclidian distances (EuD) of each OG tree with the ribosomal protein encoding tree resulted in three 
distributions of distances. To reach an alignment with high phylogenetic resolution, the sequences from 
OGs whose phylogenies were similar to the ribosomal phylogeny (EuD ≤ 0.03) were concatenated to 
the ribosomal alignment to give a single reduced ‘core’ super-alignment. Finally, polymorphic regions of 
this super-alignment were extracted and re-analyzed with RAxML using a general time-reversible (GTR) 
nucleotide substitution model. Core OG diversity was determined by comparing the average of the pair-
wise distances between the isolates per year. The reduced core super-alignment was also analyzed using 
BAPS; Bayesian Analysis of Population Structure software46 to determine the sequence clusters. Two 
runs of 40 and 50 maximum clusters were performed, each creating 12 largely monophyletic sequence 
clusters and an extra ‘sink’ cluster that incorporated all unclassified isolates. Visualization of the tree was 
performed using iTOL47.
Analysis of the population structure. Core genomes and whole genomes of strains with a capsule 
switched serotype were separately aligned in Mauve48, along with their closest neighbors (Supplementary 
File 1). SNP coordinates were isolated and characterized in Artemis49.
Genomic diversity and dynamics. The genomic diversity was determined based on the strains’ 
accessory genomes. For each OG a binary measure of presence (1) or absence (0) of a representative pro-
tein from a given strain was generated. The contribution of each strain to an OG was therefore denoted 
by a single numeric value (1 or 0) to represent the presence or absence of a gene, or a group of paralogs 
in a certain strain. This information was collated into a gene presence/absence matrix (Supplementary 
File 2). Using the method described by Dutilh et al.50, the genomic variations among strains collected 
within each year were calculated. Core OGs (those constituted of a single gene from each of the analyzed 
isolates) were excluded from this analysis.
The time frames applied to detect changes in the proportion of strains carrying a certain OG post 
PCV7 compared to before were 2001 to 2006; pre-vaccine, and 2008 to 2011; post-vaccine respectively.
Statistical analysis. The difference in phylogenetic distance among strains collected between 2001 
to 2006 and 2007 was tested by an unpaired t-test. Differences in pre- and post-vaccine gene frequencies 
were tested by Fisher Exact test. For all analyses, the significance level was set at 0.05.
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